IKT
Inhibikase Therapeutics, Inc.
$2.05
+0.07 (+3.54%)
At close · Jul 7
Market Cap
$271.99M
Shares
132,032,636
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.05
Open$1.98
Day$1.97–2.13
52W$1.33–2.26
Avg vol 30d766K
Short int18.9M · 14.3% float · 34.4d
Short vol47%
Last earningsMay 12, 2026
DataDec 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+13%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
77%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
+20%
trailing
YTD return
0%
this year
Relative strength
+12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+39% holders QoQ · +38 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.31% of float · ▲ +2.1% MoM · 34.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
103 holders — near 3-yr high, broad support
Squeeze score
96
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+58%
Y/Y
Free cash flow
$-27.8M
Balance sheet
$178.4M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
77%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+39% holders QoQ · +38 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.31% of float · ▲ +2.1% MoM · 34.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
103 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 77%
52-wk high $2
vs 200-day avg +19%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IKT
this stock
Inhibikase Therapeutics, Inc.
|
$271.99M | +0.0% | +111.0% | — | 14.3% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IKT | +6.2% | +25.8% | +19.9% | +1.0% | +0.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +5.3% | +24.4% | +12.3% | +0.9% | -9.7% |